Description

This program will cover the key clinical trial findings and their implications from ESC 2023. This program is intended for cardiovascular specialists and primary care physicians from across Canada.

Learning Objectives

• Identify the clinical implications of the new data presented at ESC 2023
• Examine where the data presented may impact clinical practice guidelines
• Apply the latest evidence-based strategies in clinical practice

Discussion Topics

• New treatments for hypertrophic cardiomyopathy
  CLEAR-Outcomes – new data with bempedoic acid in
  patients with statin intolerance
• Is there a role for semaglutide in patients with HFpEF?
• Dapagliflozin early in heart failure management
  Anticoagulation for high atrial rate episodes without AF
• Cutting edge advances in lipids, diabetes, kidney disease, and heart failure

Faculty

• Milan Gupta, MD, FRCPC, FCCS, CPC(HC)
• Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

Program slides:

A copy of the program slides is available for CCRN members with a resource library subscription. View pricing and download options on the Resources tab.